<DOC>
	<DOCNO>NCT01605032</DOCNO>
	<brief_summary>This phase II trial study well busulfan , melphalan , bortezomib first-line stem cell transplant work treat patient multiple myeloma . Giving chemotherapy peripheral blood stem cell transplant may stop growth cancer cell stop divide kill . After treatment , stem cell collect patient 's blood store . The stem cell return patient replace blood-forming cell destroy chemotherapy .</brief_summary>
	<brief_title>Busulfan , Melphalan , Bortezomib Before First-Line Stem Cell Transplant Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine complete response rate define International Myeloma Working Group ( IMWG ) criterion patient multiple myeloma treat high dose chemotherapy pharmacokinetic ( PK ) direct intravenous ( IV ) busulfan , bortezomib melphalan ( Bu/BTZ/Mel140 ) follow autologous hematopoietic stem cell transplantation ( ASCT ) first line therapy . SECONDARY OBJECTIVES : I . To determine overall response rate regimen Bu/BTZ/Mel140 . II . To determine treatment related toxicity mortality regimen , include 100-day mortality rate . III . To determine duration response , time progression , progression-free survival , event-free survival overall survival condition regimen . IV . To determine whether gender race difference pharmacokinetic profile IV busulfan . V. To determine methylation gene expression signatures pre-treatment bone marrow plasma cell explore association signatures outcome . OUTLINE : CONDITIONING : Patients receive busulfan IV 3 hour day -6 -3 , melphalan IV 20 minute day -2 , bortezomib IV 3-5 second day -6 , -3 , 1 , 4 . TRANSPLANT : Patients undergo autologous peripheral blood stem cell transplant ( PBSCT ) day 0 . After completion study treatment , patient follow 5 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients must histologically cytologically confirm multiple myeloma Measurable disease must present defined protein criterion ( quantifiable Mcomponent serum , urine serum free light chain ) order evaluate response per IMWG ; nonsecretory patient eligible provided patient &gt; 20 % plasmacytosis OR multiple ( &gt; 3 ) focal plasmacytoma focal lesion magnetic resonance imaging ( MRI ) Patients must receive induction chemotherapy myeloma , 12 month prior chemotherapy disease , must eligible first plan autologous transplant A minimum stem cell dose 2.0 x 10^6 cluster differentiation 34positive ( CD34+ ) cells/kg collect Life expectancy great 12 month Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 ( Karnofsky &gt; = 60 % ) Leukocytes &gt; = 3,000/mcL ( unless myeloma relate ) Absolute neutrophil count &gt; = 1,500/mcL ( unless myeloma relate ) Platelets &gt; = 50,000/mcL ( unless myeloma relate ) Total bilirubin = &lt; 2 x institutional upper limit normal unless 2nd Gilbert 's disease Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 3 x institutional upper limit normal Creatinine = &lt; 1.5 x institutional upper limit normal OR creatinine clearance &gt; = 60 mL/min/1.73 m^2 patient creatinine level institutional normal Ejection fraction echocardiogram ( ECHO ) multi gate acquisition scan ( MUGA ) &gt; = 40 % perform within 60 day prior registration Patients must adequate pulmonary function study : &gt; 50 % predict mechanical aspect ( forced expiratory volume one second [ FEV1 ] , force vital capacity [ FVC ] ) diffusion capacity ( diffuse capacity lung carbon monoxide [ DLCO ] ) &gt; 50 % predict , within 60 day registration ; patient unable complete pulmonary function test due multiple myeloma ( MM ) relate pain condition , exception may grant principal investigator ( PI ) document patient candidate high dose therapy Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry least six month follow stem cell transplantation ; woman become pregnant suspect pregnant participating study , inform treat physician immediately Ability understand willingness sign write informed consent document Patients chemotherapy radiotherapy within 4 week prior enter study recover adverse event due agent administer 4 week earlier Prior treatment history autologous hematopoietic stem cell transplant ( HSCT ) highdose chemotherapy stem cell rescue medical reason , limited myeloma treatment Patients may receive investigational agent Patients know brain metastasis exclude clinical trial History allergic reaction attribute compound similar chemical biologic composition agent use study , busulfan , melphalan , bortezomib , boron , mannitol Grade 2 great peripheral neuropathy within 14 day prior enrollment Unresolved grade &gt; = 3 nonhematologic toxicity previous therapy ; patient grade 2 toxicity eligible discretion PI Prior malignancy except resect basal cell carcinoma treat cervical carcinoma situ ; cancer treat curative intent &lt; 5 year allow unless approve PI ; cancer treat curative intent &gt; 5 year allow Patients must significant comorbid medical condition Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement ; patient must suffer recent ( &lt; 6 month ) myocardial infarction , unstable angina , difficult control congestive heart failure , uncontrolled hypertension , difficult control cardiac arrhythmia Pregnant woman exclude study ; breastfeed discontinue mother treated busulfan Human immunodeficiency virus ( HIV ) positive patient combination antiretroviral therapy ineligible Patients find active hepatitis B infection ( hepatitis B surface antigen + ) eligible unless meet ONE follow criterion : Patient able start dual antihepatitis ( Hep ) B therapy prior enrollment adefovir telbivudine Patient already dual antihepatitis B therapy Consultation comanagement hepatitis expert regard hepatitis B treatment strongly encourage trial Patients , positive hepatitis B core antibody , negative hepatitis B surface antigen , start lamivudine 100 mg daily least 3 month post stem cell transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>